0001209191-23-006998.txt : 20230203
0001209191-23-006998.hdr.sgml : 20230203
20230203170120
ACCESSION NUMBER: 0001209191-23-006998
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230201
FILED AS OF DATE: 20230203
DATE AS OF CHANGE: 20230203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Requadt Scott
CENTRAL INDEX KEY: 0001664852
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40384
FILM NUMBER: 23587002
MAIL ADDRESS:
STREET 1: 101 MAIN STREET, SUITE 1210
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Talaris Therapeutics, Inc.
CENTRAL INDEX KEY: 0001827506
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 570 PRESTON ST.
STREET 2: SUITE 400
CITY: LOUISVILLE
STATE: KY
ZIP: 40202
BUSINESS PHONE: 502-398-9250
MAIL ADDRESS:
STREET 1: 93 WORCESTER STREET
CITY: WELLESLEY
STATE: MA
ZIP: 02481
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-01
0
0001827506
Talaris Therapeutics, Inc.
TALS
0001664852
Requadt Scott
C/O TALARIS THERAPEUTICS, INC.
93 WORCESTER ST.
WELLESLEY
MA
02481
1
1
0
0
Chief Executive Officer
Common Stock
2022-12-30
2022-12-30
5
A
0
E
4
0.867
A
590193
D
Common Stock
449766
I
See Footnote
Stock Option (Right to Buy)
1.73
2023-02-01
4
A
0
320000
0.00
A
2033-02-01
Common Stock
320000
320000
D
Stock Appreciation Right
1.73
2023-02-01
4
A
0
320000
0.00
A
2033-02-01
Common Stock
320000
320000
D
These shares were acquired by the reporting individual under the issuer's 2021 Employee Stock Purchase Plan ("ESPP") in a transaction exempt under Rule 16b-3(c).
These shares are held by Requadt Family Limited Partnership. The reporting person has voting and dispositive power over the shares beneficially owned by Requadt Family Limited Partnership.
The shares underlying this option shall vest as follows: one-third on August 1, 2023 and the remaining two-thirds on August 1, 2024.
Each Time Vested Stock Appreciation Right ("TV SAR") represents the right to receive either, (i) the largest whole number of shares of stock with a value closest to, but not in excess of, the product of the increase in fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TV SAR, multiplied by the number of shares of common stock underlying the TV SAR that is being exercised, or (ii) the Company may elect to make cash payment measured by the increase in the fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TVSAR. One-third of the TV SAR awards will vest on August 1, 2023 and the remaining two-thirds will vest on August 1, 2024. The TV SAR awards expire on February 1, 2033 and have an exercise price of $1.73 per share, the closing price of the common stock on the grant date.
/s/ Mary Kay Fenton, attorney-in-fact
2023-02-03